Simpson Thacher is representing Wyeth, the global pharmaceuticals company, in connection with its proposed sale to Pfizer Inc. in a cash-and-stock transaction valued at approximately $68 billion. The combined entity will create one of the world’s largest and most diversified pharmaceuticals and healthcare companies. Under the terms of the merger agreement, each shareholder of Wyeth common stock will receive $33.00 in cash and 0.985 shares of Pfizer common stock.
The Simpson Thacher attorneys representing Wyeth include Casey Cogut, Eric Swedenburg, Chris May, Atif Azher, Tom Terbell, Kelly Hyunsoo Jin, Ariel Oxman, Ashwin Cheriyan, Till Lefranc and Rohith Parasuraman (M&A); Joseph Kaufman and Frank Kwok (Capital Markets); Alvin Brown and Eric Sarabia (Executive Compensation & Employee Benefits); Kevin Arquit, Joseph Tringali, David Vann, Jayma Meyer, Ketan Jhaveri, Ellen Frye and Misha Vanyo (Antritrust); James Cross (Banking & Credit); Steve Todrys and Kurt Dudas (Tax); Adeeb Fadil and Noreen Lavan (Environmental); Lori Lesser and Jennifer Rackoff (Intellectual Property); Michael Chepiga, Bob Bourque, Jonathan Youngwood, Peter Kazanoff, William Regan, Marissa Piropato, Alex Key, Justin Engel and Andrew Dempster (Litigation); Julie Levy and Andrew Janis (Labor & Employment).